NBE-002 in Patients With Advanced Solid Tumors

Summary

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

Timeline

Start

2020-06-19

Primary completion

2023-08-14

Completion

2023-08-14

Outcome

Outcome not reported

Stopped: “End of Program”

Drugs

Indications